Relay Therapeutics, Inc.
RLAY
株式のランク
#4015
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
株価
$18.65
最終同期: 2026-10-20
時価総額
$4.09B
変化（1日）
9.15%
変化（1年）
164.96%
国
US
取引 Relay Therapeutics, Inc. (RLAY)
カテゴリー
Healthcare
Relay Therapeutics, Inc.（RLAY）の収益
Jun 2026 時点の収益 TTM: $10.35M
Relay Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は $10.35M です。2023 年には $25.55M の収益があり、これは 2022 年の $1.38M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Relay Therapeutics, Inc. の収益履歴（2018 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $10.35M | 3.43% |
| 2024 | $10.01M | -60.83% |
| 2023 | $25.55M | 1,749.82% |
| 2022 | $1.38M | -54.41% |
| 2021 | $3.03M | -96.34% |
| 2020 | $82.65M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 121,873.91% |
US
|
|
| $2.23B | 21,426.57% |
US
|
|
| $15.74B | 152,019.10% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 58,076.69% |
NL
|
